A polarized morphology of leukocytes was first described to be similar to that of a migrating amoebae, with a leading edge at the front and a uropod at the rear of a migrating cell. 16 T cells recognize and bind to antigen presenting cells (APCs) through their leading edge. A number of receptors are concentrated at the leading edge, including α V β 3 , uPAR, and fMLP-R in neutrophils;
CCR2, CCR5, and FAK in T cells; and CXCR4 in B cells, which are able to sense chemotactic gradients, thus guiding leukocytes to migrate in a polarized manner. At the uropod, several reports
show localization of ICAMs, L-selectin, α M β 2 , PSGL-1, FcγR-IIIb, CD2, CD43, and CD44, 17, 18 which play a pivotal role in cell adhesion, thus facilitating cell migration. Release of the uropod triggers cell migration. Some of these receptors when bound to the substratum, become linked to the actin cytoskeleton during cell migration. Interactions between the cytoskeleton and the cell surface receptors are required for the formation of membrane protrusions, such as lamellipodia (broad, sheet-like structures) and filopodia (thin cylindrical needle-like projections), both structures located at the leading edge. 16 Several MMPs, including MT1-MMP and MMP-2 were found to colocalize at membrane protrusions. Interaction of MMPs with their natural inhibitors, TIMPs at these sites might be the key mechanism for the regulation of cell surface-MMP activation and eventually, the control of the invasive phenotype of cells.
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Cell-surface association of MMPs and other proteases
Matrix metalloproteinases (MMPs) are a family of structurally related and highly conserved zinc-dependent endopeptidases collectively capable of degrading most components of the basement membrane and ECM. 20 MMP substrates also include a wide variety of proteins, such as chemotactic molecules, adhesion molecules, proteinase inhibitors, cell surface receptors, blood clotting factors, latent growth factors and growth factor binding proteins. Most human MMPs can be divided according to their sequence homology, substrate specificity, and cellular location into several subclasses: collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and others.
The basic multidomain structure of MMPs comprises: (1) an amino-terminal domain; (2) a catalytic domain;
and (3) a carboxy-terminal domain. To date, there are at least 25 secreted or membrane-bound known human MMPs. 21 The expression, secretion, and activity of MMPs in normal tissues are subject to tight control. Data generated from intensive studies on MMP activities in different cells and tissues, as well as studies from knockout animals witness the importance of these enzymes in many normal physiological processes (e.g. embryonic development, bone resorption, angiogenesis, and wound healing) and pathological processes (rheumatoid arthritis, multiple sclerosis, periodontal disease, and tumor growth and metastasis).
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For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From MMPs are secreted as zymogens from inside the cell to the cell surface and into the extracellular environment where they are able to degrade both ECM and non-ECM proteins. It remains unclear how these enzymes make it to the correct location at the cell surface and how the proteolytic activity is controlled at the pericellular space. However, it has been suggested that MMP-binding to cell surface proteins can have an effect on intracellular signaling, can facilitate proenzyme localization and activation, mediate cell motility by disruption of cell contacts with the ECM and promote internalization of the enzyme. For example, integrins are shown to act as receptors for several proteases, including MMPs. Such interactions have been detected in caveolae, in invadopodia, and at the leading edge of migrating cells, where directed proteolytic activity is needed. The first interaction between an integrin (α V β 3 ) and a MMP (MMP-2) was identified on the surface of melanoma cells and angiogenic blood vessels ( In leukocytes, uPA could bind to its receptor, uPAR, and to α M β 2 simultaneously, forming a trimolecular complex where α M β 2 could serve as a signaling receptor. 29 This interaction is likely to be mediated by both the kringle and proteolytic domains for uPA and the I-domain for α M β 2 . This complex plays an essential role in the migration of inflammatory cells and vascular homeostasis.
The uPA/uPAR complex was also found to be associated with the α 5 β 1 integrin and capable of promoting adhesion and migration of Chinese hamster ovary cells as well as intracellular signal transduction through the integrin. In addition, a cyclic peptide DDGW discovered by phage display and a MMP-9-derived peptide motif HFDDDE, both inhibited proMMP-9/α M β 2 complex formation and leukocyte migration in vitro and in vivo. 30, 31 However, this motif did not block leukocyte adhesion to ICAM-1 and fibrinogen, suggesting the integrin-bound MMP is essential for degradation of integrin-directed bonds to matrix proteins. Recently, proMMP-9 was found to be cleavage by MMP-9 resulted in tumor cell resistance to natural killer cell-mediated cytotoxicity.
Also, a chaperone heat shock protein90 (Hsp90) was found to interact with MMP-2 on the cell surface of fibrosarcoma cells, thus promoting MMP-2 activation, which is critical for tumour invasiveness. 34 The binding mechanism of most of these interactions has not been yet elucidated.
Several cell surface hyaluronan receptor CD44 isoforms, RECK, TSP-1, LRP, and cell surface collagen IV chains also serve as MMP-9-docking molecules. The CD44/MMP-9 complex was found to be associated with invasiveness of mouse mammary carcinoma and human melanoma cells in vivo, 35 suggesting that CD44 helps to localize MMP-9 activity to the cell surface. The GPIlinked proteins RECK and TSP-1 were not only identified as cell surface receptors for MMP -9 but also were found to block their enzymatic activity. 43 The combined participation of integrins and MMPs is required for invasion of tumor cells into surrounding connective tissues, intravasation and extravasation from blood vessels, and metastasis to distant organs. 44 Indeed, studies on TIMPs have
shown that overexpression or administration of these inhibitors as recombinant proteins inhibited experimental invasion and metastasis. 45 In most cases, the stage of tumor progression correlates with the expression levels of gelatinases as the invasive and metastatic potential of tumor cells is strongly affected by changes in gelatinase expression in animal models. Expression of MMP-2 and MMP-9 was found to be strongly upregulated in cancers of lung, colon, breast, skin, and prostate which correlated with increased tumor invasiveness and metastasis.
expression in a model of experimental metastasis reduced the number of colonies formed in the lung of mice. 46 Further evidence supporting this hypothesis came from studies on MMP-2 and -9 null mice. These mice developed fewer tumors than the wild-type.
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Integrins and gelatinases in invasion and metastasis
The initial step of tumor cell invasion is characterized by the breakdown of the basement membrane, a process known to be dependent on type IV collagen-degrading enzymes, mainly MMP-2 and MMP-9. Liotta obtained results where type IV gelatinase activity correlated with cancer metastasis. 47 Endothelial cell proliferation and migration into the tumor tissue is mediated by angiogenic (ex. MMP-9, VEGF, and bFGF) and lymphangiogenic factors that are released by tumor cells. Using DNA microarrays, primary tumor-gene expression profiles could be arranged in classes of "good" and "poor" prognosis. DNA-microarray analysis on human breast carcinoma cell lines that have metastasized to bone revealed some of the genes (ex. MMP-1, MMP-2, CXCR4, IL-11, and CTGF) responsible for the increased metastatic potential of breast cancer cells. 48, 49 Videomicroscopy studies showed that MMPs play a significant role in tumor metastasis, as TIMP-1
and MMP inhibitor batimastat (BB-94) blocked the formation of tumors in secondary sites. 50 The role of MMPs in tumor invasion and metastasis has also been studied using small interfering RNAs and antisense technology. 51, 52 Gelatinases and MT-MMPs revealed a new mechanism to control metastasis by cleavage of the metastasis suppressor gene, KiSS-1. 53 Finally, recent studies supporting the in vitro data from double MMP-2:MMP-9-deficient mice demonstrated that these enzymes cooperate in promoting the invasive phenotype of malignant keratinocytes in an experimental model in vivo. 54 Changes in integrin expression and localization can also influence invasion and metastasis of tumor cells. 55 Integrins were shown to be involved in the migration and liver metastasis of large 57 Blocking integrins with synthetic peptides containing an RGD sequence, antibodies, or disintegrins (integrin-binding proteins isolated from snake venom) has been demonstrated to intefere with tumor cell invasion and metastasis in vitro and in vivo. 58 Importantly, cooperation between α v β 3 and MMP-9 increased migration of metastatic breast cancer cells. 59 Also, several reports show that uPA binding to its receptor, uPAR is a requirement for tumor cell invasion and metastasis as this process is efficiently inhibited either by an amino-terminal fragment of urokinase or a mutant plasminogen activator inhibitor-2 (PAI-2). 60 Finally, a recent study highlights the importance of chemokine receptors in breast cancer metastasis in vitro and in vivo.
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Integrins and gelatinases in cancer-associated inflammation
Chronic inflammation is also associated with a variety of cancers, including breast, liver, prostate, and skin. 43 In 70 Higher gelatinase-expression levels were detected in the bone marrow plasma of patients with leukemia compared with normal controls. After chemotherapy, the levels of TIMP-1 and TIMP-2 were significantly increased, whereas MMP-9 levels were lower in ALL and AML patients. Accordingly, AML patients who achieved a complete remission showed significantly lower MMP-9 levels, suggesting that MMP-9 could be a surrogate marker of leukemic status in these patients. Also, the low MMP-9 expression levels in patients with leukemia correlated with increased survival. 71 Several reports have demonstrated the involvement of both MMP-2/-9 gelatinases and β 2 integrins in the growth and progression of myeloid and lymphoid neoplasms. 72, 73 Selective MMP-9
expression is induced as a result of α M β 2 integrin ligation in PMNs 74 and α L β 2 integrin ligation in T lymphoma cells. 75 Also, studies from α M and α L integrin knockout mice confirm the importance of β 2 integrins in mediating leukocyte adhesion and migration. 76 In accordance, high infiltration of leukemic blasts in patients with AML strongly correlated with increased expression of both α L β 2 and α M β 2 integrins. 72 AML cell adhesion to bone marrow fibroblast monolayers seems to require both β 1 and β 2 integrins, as antibodies against them inhibited the binding. 77 Interaction between leukemic cells and bone marrow stroma cells has been shown to increase leukemic cell survival and chemotherapy-induced leukemia cell resistance. 78 Increased vessel density was detected in the bone marrow of acute and chronic leukemia patients compared with normal bone marrow, and known to be mediated by angiogenic factors such as VEGF and basic fibroblast growth factor (bFGF). 79, 80 Both increased plasma MMP-9 and VEGF correlated with high leukemia cell infiltration, suggesting that MMP-9 and VEGF act co-operatively in the process of leukemia cell invasion. 73 Another study showed that increased vessel density was mediated by MMP-2 and MMP-9 overexpression in primary AML blasts by promoting endothelial cell migration. 81 After achieving complete remission, the vessel number in AML patients was restored to normal levels. Furthermore, a gene therapy approach using a retroviral vector encoding for gelatinase inhibitors, endostatin and angiostatin strongly inhibited bone marrow angiogenesis and leukemia tumor growth in vivo. 82 These data suggest that gelatinases could be involved in collagen peptidomimetics, non-peptidomimetics, tetracycline derivatives, and biphosphonates. 83 The efficacy of these inhibitors in clinical trials is summarized in Table 2 .
The design of collagen peptidomimetic MMP inhibitors (MMPIs) is based on the collagenpeptide backbone with zinc-binding hydroxamate moiety that coordinates the Zn 2+ ion, thus inhibiting the MMP catalytic activity. An oral MMPI, marimastat significantly increased survival of patients with gastric carcinoma. Treatment with marimastat was well tolerated by the patients, except some small side effects translated with musculoskeletal pain, probably because of the need of MMPs in normal remodelling of the connective tissue of tendons and joints. In patients with advanced pancreatic cancer (a phase II study), marimastat showed comparable therapeutic effects as conventional therapy with gemcitabine that was used. 84 The survival of patients suffering from glioblastoma multiforme was also improved by using marimastat in combination with temozolomide, a cytotoxic drug. 85 Several non-peptidomimetic MMP inhibitors, including BMS-275291, AG3340, and MMI270 have also been tested in clinical trials (Table 2 ).
Tetracyclines and biphosphonates have also been shown to block MMP activity. 86 For example, a broad spectrum MMP inhibitor, metastat (or Col-3) showed increased tumor cell toxicity, reduced tumor-induced angiogenesis, as well as antimetastatic activity, 87 and is currently being tested in patients with Kaposi Sarcoma and brain cancer in a phase II clinical trial. Periostat, a tetracycline used for the treatment of periodontal diseases, is the only MMPI in the market.
Interestingly, compounds (TSRI265) capable of inhibiting interactions between MMPs and
integrins showed promising results in animal experiments. 28 Also, a cyclic peptide, CTTHWGFTLC discovered by phage display technology as a selective gelatinase inhibitor could block cell migration and tumor growth in a gelatinase-dependent manner. 88 The involvement of integrins in tumor cell invasion and metastasis became clear after using α V 89 or β 1 90 subunit-blocking antibodies or small synthetic antagonists generated from the ligand'srecognition sequence. Humanized mAbs, Vitaxin and Efalizumab against α V β 3 91 and α L subunit of α L β 2 92 respectively, and the synthetic, cyclic Arg-Gly-Asp (RGD) peptide motif 93 present in many integrin ligands were the three among many other integrin-binding agents that have entered cancer clinical trials (see Table 2 ). Efalizumab and a recombinant mAb against α 4 β 1 , natalizumab have shown a great promise in the treatment of psoriasis, 92 as well as in multiple sclerosis and Crohn's disease, respectively. 94, 95 However, β 3 and β 5 -integrin knockout mice showed increased expression of VEGFR-2 receptor, leading to enhanced tumor angiogenesis 96 . Taken together, MMP and integrin knockout models and inhibitors can increase our understanding of the multiple functions of these molecules in several diseases, including cancer. Such studies may be used to develop therapeutic agents which can interfere with the integrin and MMP function on invasive tumor cells and blood vessels.
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CONCUDING REMARKS
The failure of MMPIs in several cancer clinical trials is not surprising. 97 The physiological role of MMP-2 and -9 is not fully understood, but to our current knowledge they are involved in the processing of the extracellular matrix during growth and tissue differentiation, probably as critical factors for cell motility. Proteases and integrins for such a function have been expected to be colocalized at the surface of migrating leukocytes and other cells.
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Most MMPs, however, are secreted enzymes and the search for cell surface receptors for MMPs has been going on for years. At the moment there are some hundred publications describing receptors, such as integrins for various MMPs, among them MMP-2 and -9. Likewise, gelatinase activity has been found in the membrane of leukocytes, but the identification of the leukocyte integrins as gelatinase receptors is new to our knowledge 30,31 and likely to extend our understanding of further mechanisms involved in leukocyte migration. Studies from knockout models for integrins, including leukocyte β 2 integrins confirm their involvement in various steps of cancer development.
Eventually, tumor growth and metastasis could be blocked by interfering with integrin function on tumor cells and blood vessels.
MMP-9 has been reported to co-operate with α V β 3 integrin and α 3 β 1 integrins. MMP-9 was able to stimulate α V β 3 integrin-dependent migration of metastatic breast cancer cells and α 3 β 1 integrin-induced tumor invasion. 59 MMP-9 and uPA have been also identified as critical players in the invasion of tumors cells to the blood circulation (a process called intravasation). These proteases may act in concert with integrins, such as α V β 5 which in turn, is also required for tumor cell dissemination in a chicken chorionallantoic membrane assay. 24 We have recently shown that proMMP-9/α M β 2 complex is stored within the intracellular granules in resting PMNs and translocated to the cell surface upon cell stimulation (Figure 2 ). This is a more plausible mechanism for the MMP/integrin complex formation than binding of a secreted MMP to an unoccupied integrin on the cell surface. Also, leukocyte integrins could play a role in targeting of proMMPs to a site where proteolytic activity is needed. However, it remains to be determined by which mechanism (pro)MMP-9 is located at the surface of cells lacking β 2 integrins. integrin, resulting in reduced angiogenesis and tumor invasion. 105 Finally, a cyclic peptide, CTTHWGFTLC discovered by phage display technology as a selective gelatinase inhibitor could block leukemia cell migration and tumor growth in a gelatinase-dependent manner. 88, 30 Selective antagonists of the MMP-9/α M β 2 integrin interaction may not only be therapeutic in leukemias but also in other types of malignancies where tumor-infiltrating leukocytes enhance tumor growth. 
